Clinical Trial Update: Epoetin Alfa (EPO) in Subjects With Chronic Kidney Disease (CKD) [Phase 3]

View source ↗

Summary

A Phase 3 study of epoetin alfa in chronic kidney disease sponsored by Amgen has been terminated. The update notes the trial status but does not report results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease

Drugs mentioned

• EPOETIN ALFA (EPOETIN ALFA)

Snippet

Sponsor: Amgen | Conditions: Chronic Kidney Disease | Phase 3 | Status: TERMINATED